Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of the Autologous CAR T Cells (Tarcidomgen Kimleucel) in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

NCT06593145 is registered in ClinicalTrials.gov with FamiCordTx as lead sponsor.

NCT NCT06593145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06593145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of the Autologous CAR T Cells (Tarcidomgen Kimleucel) in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Lead sponsor
FamiCordTx
Phase
Phase 1
Overall status
Recruiting
Start date
May 24, 2023
Completion date
June 30, 2025
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), large b-cell lymphoma, mantle cell lymphoma (mcl)